Thus, intravitreal injection is now a standard clinical procedure in age-related macular degeneration (AMD) or diabetic retinopathy for the administration of anti-vascular endothelial growth factor (VEGF) therapy [15]. This evidence concerns the gene VEGFA and diabetic retinopathy.